Cancer Genetics Inc to Present on Company's Targeted

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cancer Genetics Inc to Present on Company's Targeted Next-Generation Sequencing Panels at AMP

RUTHERFORD, N.J., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX ) ("CGI" or "the Company"), an emerging leader in DNA-based cancer diagnostics, announced today that it will present on its next generation sequencing (NGS) panels for hematological malignancies at the Association for Molecular Pathology's (AMP) 2014 Annual Meeting in Harbor, MD. Principal clinical scientist Charles Ma, Ph.D., will present "Developing NGS-based Clinical Assays for Hematological Neoplasms at CGI" on Wednesday, November 12 at 3 p.m. EST. The talk, which is sponsored by Illumina, will cover the development and clinical utility of the company's NGS panels for hematologic malignancies, specifically for CLL (chronic lymphocytic leukemia) and Myeloid disorders.

Cancer Genetics currently has several targeted, disease-specific NGS panels under development, and expects to launch its Focus:: TM NGS line for clinical use by the end of 2014. The company's NGS panels for hematological malignancies will include Focus::CLL TM for chronic lymphocytic leukemia and Focus::Myeloid TM , which will have application for several myeloid diseases including myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), and acute myeloid leukemia (AML). It is estimated that in the US, nearly 100,000 individuals are currently living with MDS, and another 120,000 are living with CLL.

Tumor heterogeneity and test sensitivity remain major challenges in cancer diagnostics, and are particularly problematic in hematological cancers. NGS allows for higher sensitivity and throughput than other diagnostic technologies, and can assess a greater number of mutations and other genomic aberrations at greater resolution. As a result, NGS provides simultaneous detection of mutations in a number of critical genes with a single test. When used in conjunction with other validated clinical tests, these panels provide tremendous value for diagnostic and prognostic purposes.

"We believe that our NGS panel development reinforces our position as a leader in providing high-standard diagnostic testing for hematological malignancies," said Lan Wang, M.D., Medical Director at Cancer Genetics. "Because we can offer a variety of complementary testing services including cytogenetics, FISH, microarray, PCR/sequencing, flow cytometry, and immunohistochemistry in addition to NGS through our labs at CGI, we'll be able to provide patients and doctors with comprehensive evaluation for these cancers, and clinically actionable diagnostic and prognostic information."

Due to the improvement in sensitivity and throughput over other diagnostic tools, NGS is experiencing increasing demand within clinical diagnostics. In order to successfully translate NGS into the clinical setting, CGI has developed an efficient workflow based on Illumina technology that ensures high standards of accuracy, specificity, and sensitivity, while simultaneously meeting the rigorous needs for regulatory requirements, cost-efficiency, and rapid turnaround times.

The company will integrate Focus:: TM NGS testing into its Complete SM testing programs, which are currently available for a number of hematological and solid tumor cancers. CGI's Complete SM programs provide a suite of proprietary and conventional testing across multiple methodologies, and offer the most comprehensive diagnostic and prognostic information available.

Representatives from the company will be exhibiting at the conference at booth #1129.

About Cancer Genetics, Inc.

Cancer Genetics Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference labs are focused entirely on maintaining clinical excellence and are both CLIA certified and CAP accredited and have licensure from several states including New York State.

We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute.

For more information, please visit or follow us:

Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that the transaction will not close or, if it closes, will not realize the currently anticipated benefits, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company's Form 10-K for the year ended December 31, 2013 and 10-Q for the quarter ended June 30, 2014 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

Investor Relations Andrew McDonald Ph.D. Life Science Advisors LLC 646-597-6987 Media Relations Paul Kuntz RedChip Companies, Inc. 800-733-2447, ext. 105

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Excel Treatment Center Adds ART Trauma Therapy Option

Updated Category News Views 101

Trauma rarely arrives at an addiction program wearing a name tag. Excel Treatment Center in Dover, New Jersey, is responding to that uncomfortable reality by adding Accelerated Resolution Therapy® (ART) to the individual, group, and family therapy already available to its clients. The center says its therapists have completed ART training, and the approach is now part of...

Continue Reading
Linkind's Best Buy Push Tests Smart Outdoor Demand

Updated Category News Views 160

Holiday lights have quietly become a year-round hardware category, and Linkind wants a louder seat at the table. The smart-lighting brand says three outdoor products have been in Best Buy stores across the United States since October 17, 2026: permanent exterior lights, decorative string lights, and solar pathway lights. That is a real distribution step, not some grand...

Continue Reading
Blue Diamond's $1 Billion Brand Meets Farm Realities

Updated Category News Views 56

A Ten-Cent Signal Carries Real Weight A ten-cent edge over the industry benchmark may not excite the cocktail-party crowd, but almond growers notice every penny when fertilizer, power and pest control keep gnawing at the farm gate. Blue Diamond Growers says it delivered payments roughly 10 cents above the benchmark in its latest year, alongside net profit that came in...

Continue Reading
Kendra Scott’s Dolly Tribute Tests Purposeful Luxury

Updated Category News Views 87

Butterflies, music notes, and a $70 pendant are carrying a surprisingly serious brand message this November. Kendra Scott’s new Dolly Parton Tribute Collection is plainly built to celebrate Dolly’s style, but it also shows how a consumer brand can make sentiment do some commercial heavy lifting without turning the whole thing into mush. The collection arrived November...

Continue Reading
Chaos Zero Nightmare's Award Is a Useful Signal for Games

Updated Category News Views 239

A story award can be easy to sneer at until a live-service game earns one across three markets. Smilegate's Chaos Zero Nightmare, a dark fantasy roguelike RPG developed by Super Creative, was named Best Story in Google Play's Best of 2026 awards for Taiwan, Hong Kong and Macau. That is not a sales figure, not a profit disclosure, and certainly not proof that a hit has...

Continue Reading
Vector Adds Mesa Division 10 Veteran for Arizona Growth

Updated Category News Views 61

A toilet-partition deal rarely raises eyebrows, but this one has the sturdy logic investors ought to notice. Vector Building Products has acquired Mesa-based Partitions & Accessories Co., a Division 10 specialist that has served Arizona contractors since 1978. It is not glamorous work. It is, however, the sort of necessary, specification-driven business that gets embedded...

Continue Reading
Chemours Legal Succession Gets a Long Transition Runway

Updated Category News Views 0

A corporate-law handoff rarely sets pulses racing, but this one deserves a proper look. Chemours is replacing its long-serving general counsel while keeping the departing executive in the building for four additional months. That is not flashy, and thank goodness for that. In a global chemicals company, legal leadership touches regulation, compliance, governance,...

Continue Reading
Villa Group’s Punta Mita Bet Adds 305 Luxury Resort Keys

Updated Category News Views 102

A 12.6-acre slice of Riviera Nayarit coastline is about to get a very expensive makeover, assuming The Villa Group can turn a handsome plan into a functioning resort without the usual development headaches. The company says it has acquired a beachfront parcel in Litibú and intends to build Villa La Valencia Punta Mita, a 305-accommodation luxury property aimed squarely...

Continue Reading
Premier Energy's €850M Debt Bet on Evryo Nears Close

Updated Category News Views 27

A Bridge Loan Gives Way to a Real Commitment Eight hundred and fifty million euros is not the sort of number a company tosses around for decoration. Premier Energy has secured a five-year senior facilities agreement to fund its planned acquisition of Evryo Group, including electricity distribution subsidiary Distribu?ie Energie Oltenia S.A., and to refinance roughly...

Continue Reading
Sokin’s UAE License Turns Expansion Into Real Payments Plumbing

Updated Category News Views 106

Dubai expansion headlines are cheap; regulated local money movement is not. That is why Sokin’s newly approved Dubai Financial Services Authority license deserves more than the usual fintech applause line. The company has paired that approval with AED accounts, local payment rails, a One Za’abeel office and a plan to double its UAE staff over the next year. None of...

Continue Reading

Top 5 Most Recently Viewed Articles

Latin Metals Gears Up for Drilling at Organullo Gold Project

Updated Category News Views 176

Latin Metals Achieves Drilling Milestone for Organullo Gold Project Latin Metals Inc. (TSXV: LMS) is excited to announce that it has successfully secured a crucial permit for exploration drilling at the Organullo Gold Project. This approval is a significant step forward in their commitment to mineral exploration in Argentina. What the Drill Permit Means for Latin Metals...

Continue Reading
TheSushiDragon Partners with StreamerDap to Empower Creators

Updated Category News Views 444

TheSushiDragon Joins StreamerDap as Co-Owner In a groundbreaking move for the live streaming community, TheSushiDragon, a prominent Twitch creator, has officially entered an equity partnership with StreamerDap, a leading platform revolutionizing the sponsorship landscape for creators. This innovative partnership aims to enhance the creator experience, making sponsorships...

Continue Reading
Tariffs, Inflation Insights: What Lies Ahead for Markets

Updated Category News Views 198

Market Trends: Understanding Recent Developments The market landscape has shown itself to be quite dynamic recently. As US President Donald Trump indicates the possibility of increased tariffs, there remains a juxtaposition of hope and uncertainty in the air. While discussions of a potential peace agreement between Russia and Ukraine seem to be gaining momentum, this has...

Continue Reading
Chaos Zero Nightmare's Award Is a Useful Signal for Games

Updated Category News Views 239

A story award can be easy to sneer at until a live-service game earns one across three markets. Smilegate's Chaos Zero Nightmare, a dark fantasy roguelike RPG developed by Super Creative, was named Best Story in Google Play's Best of 2026 awards for Taiwan, Hong Kong and Macau. That is not a sales figure, not a profit disclosure, and certainly not proof that a hit has...

Continue Reading
Bloom Energy Partners with Oracle to Boost AI Infrastructure

Updated Category News Views 301

Bloom Energy and Oracle: A Strategic Collaboration Bloom Energy Corp (NYSE: BE) is experiencing a notable surge in its stock prices following a recent announcement that highlights a significant partnership with Oracle Corp (NYSE: ORCL). This new collaboration aims to utilize Bloom's innovative fuel cell technology to deliver onsite power solutions for selected Oracle...

Continue Reading